May 18, 2023 04:30PM
May 16, 2023 08:03AM
May 16, 2023 08:00AM
Apr 3, 2023 07:00AM
Jul 6, 2021 04:02PM
Jul 6, 2021 04:01PM
Apr 15, 2021 08:30AM OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma
Jan 19, 2021 08:35AM
Jan 19, 2021 08:30AM
Dec 3, 2020 09:00AM
Nov 24, 2020 09:02AM
Nov 24, 2020 09:00AM
Nov 18, 2020 09:00AM
Nov 9, 2020 08:37AM Oncosec Medical (ONCS) Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC
Nov 9, 2020 08:36AM
Nov 5, 2020 09:00AM
Nov 3, 2020 09:02AM
Nov 3, 2020 09:00AM
Oct 29, 2020 09:11AM
Oct 29, 2020 09:10AM
Aug 17, 2020 05:59AM Oncosec Medical (ONCS) Prices 4.60M Share Common Offering at $3.25/Sh
Aug 16, 2020 11:55PM
Aug 14, 2020 08:42PM
Jul 27, 2020 09:08AM
Jul 27, 2020 09:00AM
Jul 13, 2020 09:00AM
Jul 9, 2020 09:00AM
Jun 24, 2020 09:00AM OncoSec Set to Join Russel Microcap® Index
Jun 22, 2020 09:19AM
Jun 22, 2020 09:05AM
May 21, 2020 09:01AM
May 21, 2020 09:00AM
May 13, 2020 09:18AM
May 6, 2020 09:00AM
Apr 21, 2020 09:00AM OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO™ Can Be Safely Delivered and Electroporated in Liver at the Online Societ
Apr 20, 2020 09:08AM
Apr 20, 2020 09:00AM
Apr 6, 2020 09:00AM
May 28, 2019 08:30AM
May 21, 2019 08:30AM
Apr 23, 2019 08:00AM
Apr 1, 2019 08:00AM OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO™ in Refractory Metastatic Melanoma
Mar 27, 2019 08:16AM
Feb 28, 2019 08:00AM
Feb 1, 2019 08:10AM
Feb 1, 2019 08:00AM
Jan 7, 2019 08:30AM
Nov 7, 2018 08:14AM
Nov 7, 2018 08:00AM OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial
Nov 6, 2018 09:24AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All